by Fong Man Kim. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 127-137). / Abstracts in English and Chinese. / Thesis committee --- p.i / Acknowledgements --- p.ii / Abstract --- p.iii / List of figures --- p.viii / List of tables --- p.xi / Abbreviations --- p.xii / Table of contents --- p.xiv / Chapter CHAPTER 1 --- GENERAL INTRODUCTION --- p.1 / Chapter CHAPTER 2 --- LITERATURE REVIEW --- p.3 / Chapter 2.1 --- MIH from Penaeus vannamei --- p.3 / Chapter 2.1.1 --- General Introduction to P. vannamei --- p.3 / Chapter 2.1.1.1 --- Morphology --- p.3 / Chapter 2.1.1.2 --- Geographical distribution --- p.5 / Chapter 2.1.1.3 --- Economic value --- p.5 / Chapter 2.1.2 --- Physiology of Molting in Crustacean --- p.7 / Chapter 2.1.2.1 --- The molt cycle --- p.7 / Chapter 2.1.2.2 --- Physiological effects of ecdysone --- p.8 / Chapter 2.1.2.3 --- Regulation of the secretion of ecdysone --- p.9 / Chapter 2.1.2.4 --- Physiological effects of Molt-inhibiting hormone --- p.10 / Chapter 2.1.3 --- Cloning of MIH cDNA from P. vannamei --- p.14 / Chapter 2.1.3.1 --- Molecular identity of MIH --- p.14 / Chapter 2.1.3.2 --- Cloning of MIH cDNA --- p.15 / Chapter 2.1.3.3 --- Comparison of the cloned MIH-like cDNA with the CHH/MIH/VIH peptide family --- p.16 / Chapter 2.2 --- Plants as Bioreactors --- p.20 / Chapter 2.2.1 --- Principles & Techniques --- p.20 / Chapter 2.2.2 --- Advantages of plant bioreactors --- p.21 / Chapter 2.2.3 --- Tobacco expression system --- p.22 / Chapter 2.2.3.1 --- Tobacco as model plants --- p.22 / Chapter 2.2.3.2 --- Transformation methods --- p.23 / Chapter 2.2.4 --- Phaseolin --- p.26 / Chapter CHAPTER 3 --- EXPRESSION OF MIH IN TRANSGENIC TOBACCO --- p.28 / Chapter 3.1 --- Introduction --- p.28 / Chapter 3.2 --- Materials & Methods --- p.29 / Chapter 3.2.1 --- Chemicals --- p.29 / Chapter 3.2.2 --- Plant materials --- p.29 / Chapter 3.2.3 --- Bacterial strains and plasmid vectors --- p.30 / Chapter 3.2.4 --- Construction of chimeric genes - --- p.30 / Chapter 3.2.4.1 --- PCR amplification of MIH --- p.30 / Chapter 3.2.4.2 --- Cloning of PCR-amplified MIH into vector pET --- p.31 / Chapter 3.2.4.3 --- Cloning of MIH into vector pBK/Phas-sp and pTZ/Phas --- p.31 / Chapter 3.2.4.4 --- Cloning of MIH into binary vector pBI121 --- p.32 / Chapter 3.2.5 --- Transformation of Agrobacterium with pBI121/Phas-sp-MIH and pBI121 /Phas-MIH by electroporation --- p.39 / Chapter 3.2.6 --- Transformation of tobacco --- p.40 / Chapter 3.2.7 --- Selection of transgenic plants --- p.41 / Chapter 3.2.8 --- GUS assay --- p.42 / Chapter 3.2.9 --- Extraction of leaf genomic DNA --- p.43 / Chapter 3.2.10 --- Extraction of total RNA from developing seeds --- p.44 / Chapter 3.2.11 --- Synthesis of DIG-labeled DNA and RNA probes --- p.45 / Chapter 3.2.12 --- Southern blot analysis of genomic DNA --- p.47 / Chapter 3.2.13 --- Reverse transcriptase - polymerase chain reaction (RT-PCR) --- p.47 / Chapter 3.2.14 --- Northern blot analysis of total RNA --- p.48 / Chapter 3.2.15 --- Protein extraction and tricine-SDS-PAGE --- p.49 / Chapter 3.2.16 --- Purification of 6xHis-tag proteins --- p.50 / Chapter 3.2.17 --- Western blot analysis --- p.50 / Chapter 3.2.18 --- In vitro transcription & translation --- p.52 / Chapter 3.2.18.1 --- Construction of transcription vector containing the chimeric MIH gene --- p.52 / Chapter 3.2.18.2 --- In vitro transcription --- p.56 / Chapter 3.2.18.3 --- In vitro translation --- p.56 / Chapter 3.2.19 --- Particle bombardment --- p.57 / Chapter 3.2.19.1 --- Construction of MIH-GUSN fusion chimeric genes --- p.57 / Chapter 3.2.19.2 --- Conditions of particle bombardment --- p.63 / Chapter 3.2.20 --- Codon modification of MIH gene --- p.63 / Chapter 3.3 --- Results --- p.73 / Chapter 3.3.1 --- Construction of chimeric MIH genes --- p.73 / Chapter 3.3.2 --- "Tobacco transformation, selection and regeneration" --- p.73 / Chapter 3.3.3 --- Detection of GUS activity --- p.74 / Chapter 3.3.4 --- Southern blot analysis --- p.79 / Chapter 3.3.5 --- Detection of MIH transcript in transgenic tobacco --- p.83 / Chapter 3.3.5.1 --- RT-PCR --- p.83 / Chapter 3.3.5.2 --- Northern blot analysis --- p.86 / Chapter 3.3.6 --- Detection of MIH protein by Tricine-SDS-PAGE --- p.86 / Chapter 3.3.7 --- Detection of MIH protein by western blot analysis --- p.88 / Chapter 3.3.7.1 --- Western blot analysis using Anti-MIH antibody --- p.88 / Chapter 3.3.7.2 --- Western blot analysis using Anti-His antibody --- p.90 / Chapter 3.3.7.3 --- Western blot analysis using Anti-MIHA & Anti-MIHB antibodies --- p.90 / Chapter 3.3.8 --- Purification of 6xHis-tag proteins by Ni-NTA column --- p.94 / Chapter 3.3.8.1 --- Western blot analysis of proteins purified by Ni-NTA column --- p.97 / Chapter 3.3.9 --- In vitro transcription and translation --- p.100 / Chapter 3.3.9.1 --- In vitro transcription --- p.100 / Chapter 3.3.9.2 --- In vitro translation --- p.100 / Chapter 3.3.10 --- Particle bombardments --- p.103 / Chapter 3.3.10.1 --- Transient expression of MIH in soybean & tobacco leaves --- p.103 / Chapter CHAPTER 4 --- DISCUSSION --- p.107 / Chapter 4.1 --- Transient expression of MIH genes --- p.109 / Chapter 4.1.1 --- In vitro transcription and translation --- p.109 / Chapter 4.1.2 --- Particle bombardments --- p.220 / Chapter 4.2 --- Post-transcriptional gene silencing (PTGS) --- p.114 / Chapter 4.2.1 --- Post-transcriptional cis-inactivation --- p.114 / Chapter 4.2.2 --- Post-transcriptional trans-inactivation --- p.116 / Chapter 4.2.3 --- MIH gene and PTGS --- p.118 / Chapter 4.3 --- Codon usage --- p.119 / Chapter 4.3.1 --- Codon usage of MIH in plants --- p.120 / Chapter 4.3.2 --- Codon modification of MIH and further study on MIH expression in plants --- p.122 / Chapter 4.4 --- Post-translational protein degradation --- p.123 / Chapter 4.4.1 --- Construction of LRP-MIH fusion proteins --- p.123 / CONCLUSION --- p.125 / REFERENCES --- p.127

L’hypothalamus est une aire cérébrale clé pour le contrôle de la prise alimentaire et des dépenses énergétiques ; en intégrant des signaux périphériques (hormones, nutriments). Une inflammation dans l’hypothalamus pourrait perturber le fonctionnement de ce dernier, dérégulant l’homéostasie énergétique et induire une perte de poids ou l’obésité. Nous avons cherché à identifier les relais moléculaires entre l’inflammation et les systèmes neuropeptidergiques hypothalamiques régulant l’homéostasie énergétique, en nous concentrant sur les chimiokines. D’une part, nous avons montré que le récepteur CCR2 participe à la perte de poids liée à une inflammation aigue induite chez la souris par l’injection centrale de lipopolysaccharide bactérien, possiblement en induisant l’inhibition de l’activité des neurones hypothalamiques à MCH, peptide aux effets orexigènes. D’autre part, nous avons étudié les liens entre inflammation hypothalamique, gain de poids et/ou la consommation de régimes hyperlipidiques pouvant induire à terme une obésité. Nous avons trouvé, chez la souris, que 1) la chimiokine CCL5 favoriserait la prise de poids, possiblement en activant les neurones hypothalamiques à MCH ; 2) la nature des lipides d’un régime hyperlipidique impacterait la cinétique de développement de l’obésité, avec des changements du profil inflammatoire et 3) la consommation excessive de lipides induirait une gliose très précoce dans l’hypothalamus. L’ensemble de nos résultats souligne l’intérêt de cibler l’inflammation hypothalamique dans ces pathologies et identifient les chimiokines comme cibles thérapeutiques potentielles dans le traitement des dérégulations de la balance énergétique. / The hypothalamus is a key brain region in the regulation of energy homeostasis, in particular by controlling food intake and energy storage and expenditure by integration of peripheral humoral and nutrient-related signals. Hypothalamic inflammation could alter hypothalamic function, thus deregulate energy homeostasis and induce weight-loss or obesity. We sought to identify mediators that could act as intermediaries between inflammation and neuropeptidergic systems of the hypothalamus that are involved in the regulation of energy homeostasis, focusing on chemokines. First, we studied the effect of a central injection of bacterial lipopolysaccharide, mimicking a acute and strong inflammation state in mice. We identified the receptor CCR2 as a central actor in the weight-loss induced by this treatment, possibly by direct inhibitory effects on hypothalamic neurons expressing MCH, a peptide known to have orexigenic and energy conservative effects. Second, we studied links between hypothalamic inflammation, weight-gain and/or high-fat diets consumption that can induce, eventually, obesity. We found in mice that: 1) the chemokine CCL5 would promote weight-gain, possibly by enhancing the activity of hypothalamic MCH neurons; 2) altering the lipid composition of a high-fat diet changes the kinetics of the development of diet-induced obesity, together with changes in the inflammatory profile and 3) an excessive dietary lipid intake can induce very early gliosis in the hypothalamus. Taken together, our results underline the interest of reducing hypothalamic inflammation to fight feeding behavior deregulations and identify chemokines as putative therapeutic targets.

Les neurotrophines sont des facteurs de croissance initialement découverts dans le système nerveux et ayant pour rôle de contrôler la croissance, la prolifération et la survie des cellules neuronales et astrocytaires, mais aussi dans de nombreux autres tissus. Les neurotrophines peuvent interagir avec leurs récepteurs de haute affinité Trks. Les travaux précédemment réalisés au sein de notre équipe ont mis en évidence une boucle de régulation autocrine, en réponse à un stress cellulaire, et ce de façon dépendante des neurotrophines, notamment du BDNF, dans plusieurs lignées lymphocytaires B humaines, à différents stades de différenciation. Les cellules produisent du BDNF qui agit de manière autocrine sur son récepteur spécifique, TrkB. Le transport du BDNF est assuré par la sortiline, une protéine à domaine Vps10. Les neurotrophines sont également synthétisées sous forme de progéniteurs biologiquement actifs, les pro-neurotrophines. Le pro-BDNF interagit avec le récepteur aux neurotrophines à domaine de mort p75NTR, l’interaction du pro-BDNF avec le récepteur p75NTR et de son co-récepteur, la sortiline, induit l’apoptose des lymphocytes B. La sortiline est exprimée dans les lymphocytes B humains, les lignées de lymphocytaires B. La sortiline, également appelée NTSR3, peut lier un autre neuropeptide, la neurotensine (NTS). Identifiée, dans le système nerveux, où elle joue un rôle de neurotransmetteur, impliqué dans l’analgésie et la thermorégulation. Elle est également présente dans le tube digestif, où elle est impliquée dans la régulation de la digestion et le contrôle et de la glycémie. La fonction de la neurotensine est associée à l’activation de la sortiline mais aussi de ses deux récepteurs à protéine G, le récepteur de haute affinité, NTSR1 et le récepteur de faible affinité, NTSR2. La NTS est impliquée dans l’oncogenèse de nombreux cancers solides via sa liaison au récepteur NTSR1 principalement mais également au récepteur NTSR2, notamment dans un modèle de cancer prostatique. Nous avons démontré pour la première fois l’expression de la neurotensine et de ses récepteurs NTSR1 et NTSR2 dans les lymphocytes B humains. Le stress pro-apoptotique induit par la privation sérique favorise une relocalisation des récepteurs NTSR1 et sortiline à la membrane plasmique. Au sein de ces cellules, la neurotensine induit une augmentation de la prolifération et une diminution de l’apoptose. Ces effets de la NTS sont bloqués par l’inhibiteur de NTSR1, le SR48692/Meclinertant®. Les analyses transcriptionnelles ont détecté une surexpression du récepteur NTSR2 au sein des lymphocytes B purifiés de patients ayant une LLC et au niveau des ganglions de patients atteints de lymphomes B en revanche, l’expression de la neurotensine est réduite. La surexpression de NTSR2 induit l’activation transcriptionnelle de TrkB, autre récepteur exprimé par ces lignées comme par les cellules de LLC de patients. La co-localisation de ces 2 récepteurs a été démontrée. Ce complexe protéique induit l’activation des voies de signalisation ERK, p38MAPK et JNK, après traitement par le BDNF, le ligand de TrkB. Ces données suggèrent un phénomène de transactivation entre ces 2 récepteurs, dépendant des métalloprotéases. Le blocage de l’internalisation de ce complexe protéique, induit une augmentation de l’activation des voies de signalisation. Le trafic intra-cellulaire endosomal de ce complexe apparaît perturbé dans les cellules surexprimant NTSR2, ce qui pourrait conduire à son accumulation comme cela est détecté dans les cellules de LLC. Ces cellules leucémiques se caractérisent également par une production d’exosomes contenant le complexe TrkB/NTSR2, sécrété en extra-cellulaire et retrouvé en excès dans le plasma des patients en comparaison à des témoins volontaires sains. / Neurotrophins are growth factors, initially discovered in the nervous system and whose functions are implicated in the growth, proliferation and survival of neuronal cells and astrocytes, and also in many other tissues. Neurotrophins can interact with their high-affinity receptors Trks. Previous work in our team showed a neurotrophin-dependent survival autocrine loop in response to cellular stress, including BDNF in several human B cell lines at various stages of B lymphocytes differentiation. These cells produce BDNF which acts in an autocrine manner on its specific tyrosine kinase receptor, TrkB. BDNF transport is provided by a Vps10 domain protein named, sortilin. Neurotrophins are synthesized as biologically active precursors, pro-neurotrophins. The proBDNF may interact with a death domain neurotrophins receptor p75NTR. The interaction of proBDNF with the p75NTR receptor and its co-receptor sortilin, induces B cell apoptosis. Sortilin is expressed in human lymphocytic lines B. Sortilin can bind another neuropeptide, neurotensin (NTS) and also called NTSR3 (Neurotensin Receptor 3). Identified in the nervous system, where it acts as a neurotransmitter involved in analgesia and thermoregulation, NTS is also present in the digestive tract, and involved in the digestion and glucose regulations. Neurotensin functions are associated to the sortilin activation but also its two G-protein coupled receptors, the high and the low affinity receptors, NTSR1 and NTSR2 respectively. NTS is involved in the oncogenesis of many solid cancers, especialy by its binding to the receptor NTSR1 mainly, but also NTSR2 notably in a prostate cancer model. We have demonstrated for the first time the expression of neurotensin and its receptors NTSR1 and NTSR2 in human B lymphocytes. The pro-apoptotic stress induced by serum deprivation promotes relocation NTSR1 receptor sortilin and to the plasma membrane. Within these cells, neurotensin induces increased proliferation and decreased apoptosis. These effects are blocked by the NTSR1 antagonist, SR48692/Meclinertant®. Transcriptional analyzes have detected overexpression of the receptor NTSR2 in purified B cells from patients with CLL and in lymph nodes of B-cell lymphomas patients, in contrast, the expression neurotensin is reduced. Overexpression NTSR2 induced transcriptional activation of TrkB. This receptor is expressed by B cell lines and B cells of CLL patients. The co-localization of these 2 receptors was demonstrated. This protein complex induces the activation of signaling pathways ERK, JNK and p38MAPK, after treatment with BDNF, the TrkB ligand. These data suggest a transactivation between these two receptors, depending to the metalloproteas activation. The internalization blocking of this protein complex, induces its plasma membrane sequestration and induces an increase of the signaling pathways activation. The intracellular endosomal trafficking in cells overexpressing NTSR2 cells, as detected in CLL cells, appears disrupted, which might lead to the NTSR2/TrkB complex accumulation, and releasing to the extracellular environnement. These leukemic cells are also characterized by a production of exosomes containing the TrkB/NTSR2 complex, secreted to the extracellular environement and found in excess in the plasma of patients in comparison to healthy volunteers.

La sclérose en plaques (SEP) est une maladie autoimmune inflammatoire et neurodégénérative du système nerveux central (SNC) chez le jeune adulte résultant d’une altération ciblée de la myéline. Les premiers symptômes de la SEP sont une détérioration cognitive, des vertiges, des douleurs, de la fatigue et une perte de la vision. En condition physiologique, les axones des neurones sont entourés par une gaine de myéline synthétisée par les oligodendrocytes permettant d’accélérer la vitesse de conduction des influx nerveux et de prévenir la mort neuronale. Le modèle expérimental le plus utilisé dans l’étude des mécanismes de la SEP est le modèle de l’encéphalomyélite autoimmune expérimentale (EAE). Après une immunisation contre la glycoprotéine oligodendrocytaire de la myéline 35-55 (MOG35-55), les lymphocytes T Cluster of differentiation (CD)4+ helper (Th)1 et Th17 auto-réactifs induisent une réponse inflammatoire aiguë à la périphérie puis migrent dans le SNC. Ils provoquent alors une réponse inflammatoire dirigée contre la myéline, avec l’intervention descellules myéloïdes. Cela aboutit à la destruction des gaines de myéline diminuant la vitesse de conduction des influx nerveux et une perte axonale, responsables des symptômes mentionnés précédemment. A l’heure actuelle, les traitements contre la SEP peuvent ralentir la progression de la paralysie et diminuer la sévérité ainsi que l’incidence des symptômes diminuant l’inflammation. En revanche, ils n’ont pas d’effets sur les formes progressives de la maladie au cours desquellesles processus neurodégénératifs s’amplifient et dominent ceux de l’inflammation. Il est donc nécessaire de trouver de nouvelles thérapies qui pourront à la fois bloquer l’inflammation et promouvoir la remyélinisation et la neurorégénération. Dans cette optique, de nouvelles cibles thérapeutiques ont émergé pour traiter la SEP : le Vasoactive Intestinal Peptide (VIP), le Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), l’orexine A, leurs récepteurs ainsi queleurs analogues. En effet, ces neuropeptides présentent des activités anti-inflammatoires et neuroprotectrices. Mes travaux de thèse ont porté sur l’étude des effets d’un agoniste de VPAC2, l’un des récepteurs de VIP et PACAP, et de l’orexine A sur les processus inflammatoires et neurodégénératifs dans le modèle d’EAE ainsi que dans le modèle toxique de la cuprizone (CPZ), induisant la mort des oligodendrocytes matures et la démyélinisation indépendamment des lymphocytes T. Après une immunisation contre la MOG35-55, un traitement systémique de court durée avec BAY55-9837, un agoniste de VPAC2, diminue la sévérité de l’EAE chronique en diminuant la réponse inflammatoire à la périphérie avec une baisse de l’activation lymphocytaire, de l’activité de présentation antigénique des cellules dendritiques et des monocytes ainsi qu’une modulation de la population des lymphocytes T régulateurs. Au niveau de la moelle épinière, l’infiltration descellules immunitaires est moindre et la proportion en microglie/macrophages est plus élevée après traitement par l’agoniste de VPAC2. De plus, BAY55-9837 diminue les processus de démyélinisation et favorise ceux de remyélinisation dans le modèle de la CPZ. En parallèle, l’administration intrapéritonéale à court terme de l’orexine A diminue drastiquement la sévérité de l’EAE chronique. Le traitement ne présente pas d’effet sur la phase d’immunisation de l’EAE mais limite la phase effectriceavec une diminution de l’infiltration des lymphocytes T CD4+, des médiateurs inflammatoires, de la démyélinisation, de l’astrogliose et de l’activation microgliale au niveau du SNC. Par contre, l’administration systémique de l’orexine A ne semble pas avoir d’effet sur les phases de démyélinisation et de remyélinisation au cours du modèle de la CPZ / Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS). First MS symptoms are cognitive deterioration, dizziness, pain, fatigue and loss of vision. In physiological condition, the axons of neurons are surrounded by a myelin sheath synthesized by oligodendrocytes to accelerate the conduction velocity of nerve impulses and to prevent neuronal death. The most widely used experimental model of MS is the EAE model. After immunization against MOG35-55, self-reactive Th1 and Th17 cells induce an acute inflammatory response at the periphery and then migrate into the SNC. Then they induce an inflammatory response against myelin, with the intervention of myeloid cells. This results in the destruction of myelin sheaths decreasing the rate of conduction of nerve impulses and axonal loss, responsible for the aforementioned symptoms. Currently, MS treatments can slow the progression of paralysis and decrease the severity and the incidence of symptoms by targeting immune responses. However, these treatments have no effect on the progressive forms of the disease when the neurodegenerative processes amplify and dominate the inflammatory component. It is therefore necessary to find effective therapies that can both block inflammation and also promote remyelination and neuroregeneration.In this context, new therapeutic targets have emerged to treat MS: VIP, PACAP, orexin A, their receptors and their analogs. These neuropeptides have several effects such as anti-inflammatory and neuroprotective activities. My thesis works were focused on the effect of a VPAC2 receptor agonist, one of the three receptors of VIP and PACAP, and orexin A in inflammatory and neurodegenerative processes during MOG35-55-induced EAE model and toxic model using CPZ, which induces mature oligodendrocyte death and demyelination without the influence of lymphocytes.A short term and systemic treatment of BAY55-9837, a VPAC2 agonist, decreases chronic EAE severity with less activation of T lymphocytes and antigen presentation activities of dendritic cells and monocytes as well as Treg population modulation at the periphery. In the CNS, immune cell infiltration is reduced in VPAC2-treated mice compared to PBS-treated mice with an higher microglia/macrophage proportion. Moreover, VPAC2 agonist decreases demyelination processes and enhances remyelination during cuprizone model. In parallel, short term and intraperitoneal administration of orexin A decreases drastically the severity of chronic EAE. Orexin A treatment has no effect on immunization phase of EAE but limits effective phase with a lower infiltration of CD4+ T lymphocytes, inflammatory mediators, demyelination, astrogliosis and microglial activation in the CNS. In contrast, systemic administration of orexin A seems to have no effect during demyelination and remyelination phases in CPZ model.

Gut regulatory peptides, such as neuropeptides and incretins, play important roles in hunger, satiety and gastrointestinal motility, and possibly mucosal permeability. Many peptides secreted by myenteric nerves that regulate motor control are also produced in mucosal epithelial cells. Derangements in motility and mucosal permeability occur in many diseases. Current knowledge is fragmentary regarding gut peptide actions and mechanisms in motility and permeability. This thesis aimed to 1) develop probes and methods for gut permeability testing, 2) elucidate the role of neuropeptide S (NPS) in motility and permeability, 3) characterize nitrergic muscle relaxation and 4) characterize mechanisms of glucagon-like peptide 1 (GLP-1) and the drug ROSE-010 (GLP-1 analog) in motility inhibition. A rapid fluorescent permeability test was developed using riboflavin as a transcellular transport probe and the bisboronic acid 4,4'oBBV coupled to the fluorophore HPTS as a sensor for lactulose, a paracellular permeability probe. This yielded a lactulose:riboflavin ratio test. NPS induced muscle relaxation and increased permeability through NO-dependent mechanisms. Organ bath studies revealed that NPS induced NO-dependent muscle relaxation that was tetrodotoxin (TTX) sensitive. In addition to the epithelium, NPS and its receptor NPSR1 localized at myenteric nerves. Circulating NPS was too low to activate NPSR1, indicating NPS uses local autocrine/paracrine mechanisms. Nitrergic signaling inhibition by nitric oxide synthase inhibitor L-NMMA elicited premature duodenojejunal phase III contractions in migrating motility complex (MMC) in humans. L-NMMA shortened MMC cycle length, suppressed phase I and shifted motility towards phase II. Pre-treatment with atropine extended phase II, while ondansetron had no effect. Intestinal contractions were stimulated by L-NMMA, but not TTX. NOS immunoreactivity was detected in the myenteric plexus but not smooth muscle. Food-intake increased motility of human antrum, duodenum and jejunum. GLP-1 and ROSE-010 relaxed bethanechol-induced contractions in muscle strips. Relaxation was blocked by GLP-1 receptor antagonist exendin(9-39) amide, L-NMMA, adenylate cyclase inhibitor 2´5´-dideoxyadenosine or TTX. GLP-1R and GLP-2R were expressed in myenteric neurons, but not muscle. In conclusion, rapid chemistries for permeability were developed while physiological mechanisms of NPS, nitrergic and GLP-1 and ROSE-010 signaling were revealed. In the case of NPS, a tight synchrony between motility and permeability was found.

published_or_final_version / abstract / Zoology / Master / Master of Philosophy

Ependymin (EPN) is a goldfish brain neurotrophic factor (NTF) previously shown to function in a variety of cellular events related to long-term memory formation and neuronal regeneration. Because of these functions, EPN and other NTFs have potential applications for treating neuro-degenerative conditions, including stroke. In previous experiments, our lab in collaboration with Victor Shashoua of Ceremedix Inc (Boston, MA), designed short synthetic peptide CMX-8933 (a proteolytic cleavage product of EPN) and CMX-9236 (an EPN-Calmodulin combination peptide) that mimic the action of full-length EPN. In a rat stroke model, administration of these peptides i.v. significantly lowered brain ischemic volume (Shashoua et al., 2003). Because oxidative stress is one of the primary mediators of cell damage following a stroke, we hypothesized that NTFs, and in particular our therapeutic peptides, may act in part by reducing neuronal oxidative stress. Thus, the purpose of this thesis was to determine whether CMX-8933 and CMX-9236 increase the cellular titers of anti-oxidative enzymes. A hybridization array was used as a“hypothesis generator" to obtain candidates for further analysis. This approach applied to rat primary brain cortical cells treated with CMX-8933 identified superoxide dismutase (SOD) as strongly upregulated. SOD immunoblots on whole cell lysates, and RT-PCR on total cellular RNA, were used to confirm this observation. In time-course and dose-response experiments, treatment of rat primary cortical cultures with either peptide showed an optimal 8.5 fold (N = 5, p < 0.001) increase in SOD protein, while administration of CMX-8933 to murine neuroblastoma cells caused a 6.5 fold (N = 3, p = 0.001) increase in SOD mRNA levels. Previous work in other laboratories indicated that systemic (i.v.) administration of full-length NTFs allows only an inefficient delivery across the blood brain barrier (BBB). We hypothesized that our short synthetic peptides may cross the BBB more efficiently. Immunoblot analysis of brains and hearts excised from mice treated i.v. with various doses of CMX-8933 confirmed the elevated SOD titers (10 fold in brain, and 8 fold in heart, at a 6 mg/kg dose for 5 hr; N = 5, p < 0.001). Furthermore, we hypothesized that conjugation of CMX-8933 to BBB carrier DHA, a natural neuronal membrane fatty acid shown previously to enhance the delivery of dopamine to the brain (Shashoua and Hesse, 1996), might further enhance the NTF therapy. Delivery of DHA-8933 increased SOD expression by 3 fold (N = 4, p < 0.001) relative to non-conjugated CMX-8933. Recently, the use of special incubators that allow the culture of cells under low oxygen conditions (anoxia) has been used as an in vitro model for stroke. When we tested our peptides in this new in vitro model, surprisingly SOD was upregulated 3 fold (N = 3, p = 0.003) in rat primary cortical cells cultured for 24 hr under oxygen deprivation, compared to normoxic conditions. This implies that these rat cultures may have an endogenous cellular system for responding to oxygen stress, a finding worthy of further investigation. Treatment of anoxic cells with CMX-8933 increased SOD levels another 2.8 fold (N = 3, p < 0.001) compared to the levels for anoxia alone (for a total of 8.5 fold relative to normoxic cells). Altogether, the data from this thesis illustrate that small NTF EPN peptide mimetics increase the cellular titers of the mRNA and protein for the anti-oxidative enzyme SOD, which may be an important step in their known therapeutic benefits.

by Lo Ming Yip. / "July 1998." / Thesis (Ph.D.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (p. 208-247). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstract in Chinese.

Zhang Jie. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 54-74). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.i / ABSTRACT --- p.ii / ABSTRACT (Chinese) --- p.iv / ABBREVIATION --- p.vi / Chapter CHAPTER 1 --- INTRODUCTION --- p.1 / Chapter 1.1 --- Overview of the study --- p.1 / Chapter 1.2 --- Secretin --- p.3 / Chapter 1.2.1 --- Discovery / Chapter 1.2.2 --- Molecular biology / Chapter 1.2.3 --- Biosynthesis and localization / Chapter 1.2.4 --- Function / Chapter 1.3 --- Secretin receptor --- p.8 / Chapter 1.3.1 --- Molecular biology / Chapter 1.3.2 --- Localization / Chapter 1.3.3 --- Signal transduction pathway / Chapter 1.4 --- Secretin and autism --- p.13 / Chapter 1.5 --- AMPA receptor --- p.15 / Chapter 1.5.1 --- Molecular biology / Chapter 1.5.2 --- Localization / Chapter 1.5.3 --- Pharmacological property / Chapter 1.5.4 --- Function / Chapter 1.6 --- Cerebellum --- p.20 / Chapter 1.6.1 --- Structure of the cerebellar cortex / Chapter 1.6.2 --- Neurons of the cerebellar cortex / Chapter 1.6.2.1 --- Granule cells / Chapter 1.6.2.2 --- Purkinje cells / Chapter 1.6.2.3 --- Basket and stellate cells / Chapter 1.6.2.4 --- Golgi cells / Chapter 1.6.3 --- Intrinsic circuitry of the cerebellar cortex / Chapter CHAPTER 2 --- METHODS AND MATERIALS --- p.25 / Chapter 2.1 --- Brain slice preparation and maintenance --- p.25 / Chapter 2.2 --- Experimental set-up --- p.26 / Chapter 2.2.1 --- Visualization of neurons / Chapter 2.2.2 --- Electrophysiological recordings / Chapter 2.2.3 --- Evoked stimulation / Chapter 2.2.4 --- Drug preparation and administration / Chapter 2.3 --- Data analysis --- p.29 / Chapter 2.3.1 --- Construction of dose-response curve / Chapter 2.3.2 --- Analysis of synaptic currents / Chapter 2.3.3 --- Statistics / Chapter CHAPTER 3 --- RESULTS --- p.31 / Chapter 3.1 --- Basic characteristics of IPSCs recorded from PCs --- p.31 / Chapter 3.1.1 --- Spontaneous IPSCs / Chapter 3.1.2 --- Miniature IPSCs / Chapter 3.1.3 --- Evoked IPSCs / Chapter 3.1.4 --- Rundown of IPSCs / Chapter 3.2 --- Electrophysiological effects of secretin --- p.33 / Chapter 3.2.1 --- Effects of secretin on evoked IPSCs and EPSCs / Chapter 3.2.2 --- Effects of secretin on spontaneous IPSCs / Chapter 3.2.3 --- Effects of secretin on miniature IPSCs / Chapter 3.3 --- Mechanisms of secretin as a neuropeptide --- p.37 / Chapter 3.3.1 --- Non-involvement of a postsynaptic site of action / Chapter 3.3.2 --- Non-involvement of calcium influx / Chapter 3.3.3 --- Involvement of cAMP second messenger / Chapter 3.3.4 --- Involvement of presynaptic AMP A receptors / Chapter 3.3.4.1 --- Glutamate-mediated action of secretin / Chapter 3.3.4.2 --- Effects of AMPA on miniature IPSCs / Chapter 3.3.4.3 --- Pharmacological evidence / Chapter CHAPTER 4 --- DISCUSSION --- p.45 / Chapter 4.1 --- Secretin as a novel neuropeptide --- p.45 / Chapter 4.2 --- Mechanisms of secretin --- p.46 / Chapter 4.3 --- Physiological role of secretin in the cerebellum --- p.52 / Chapter 4.4 --- Secretin and autism --- p.52 / REFERENCES --- p.54

The intracranial system consists of three main basic components - the brain, the blood and the cerebrospinal fluid. The physiological processes of each of these individual components are complex and they are closely related to each other. Understanding them is important to explain the mechanisms behind neurostructural disorders such as hydrocephalus. This research project consists of three interrelated studies, which examine the mechanical properties of the brain at the macroscopic level, the mechanics of the brain during hydrocephalus and the study of fluid hydrodynamics in both the normal and hydrocephalic ventricles. The first of these characterizes the porous properties of the brain tissues. Results from this study show that the elastic modulus of the white matter is approximately 350Pa. The permeability of the tissue is similar to what has been previously reported in the literature and is of the order of 10-12m4/Ns. Information presented here is useful for the computational modeling of hydrocephalus using finite element analysis. The second study consists of a three dimensional finite element brain model. The mechanical properties of the brain found from the previous studies were used in the construction of this model. Results from this study have implications for mechanics behind the neurological dysfunction as observed in the hydrocephalic patient. Stress fields in the tissues predicted by the model presented in this study closely match the distribution of histological damage, focused in the white matter. The last study models the cerebrospinal fluid hydrodynamics in both the normal and abnormal ventricular system. The models created in this study were used to understand the pressure in the ventricular compartments. In this study, the hydrodynamic changes that occur in the cerebral ventricular system due to restrictions of the fluid flow at different locations of the cerebral aqueduct were determined. Information presented in this study may be important in the design of more effective shunts. The pressure that is associated with the fluid flow in the ventricles is only of the order of a few Pascals. This suggests that large transmantle pressure gradient may not be present in hydrocephalus.